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ntermittent presumptive treatment 
(IPT) in pregnancy involves 
giving a curative treatment dose 
of an effective antimalarial drug at 
predeﬁ  ned intervals during pregnancy. 
IPT in pregnancy was ﬁ  rst introduced 
in areas of high malaria transmission 
as a measure to reduce the adverse 
impact of Plasmodium falciparum malaria 
in pregnancy [1,2,3,4,5,6,7,8]. Later, 
based on trials showing that IPT could 
reduce anaemia in young children 
and also malaria episodes in infants, it 
was extended as a measure to reduce 
morbidity and mortality in the ﬁ  rst year 
of life [9,10,11,12]. 
Antimalarial chemoprophylaxis for 
pregnant women living in endemic 
areas has been recommended for 
many years, but in practice has been 
limited to the use of chloroquine and 
pyrimethamine [13,14]. Unfortunately, 
there are few places left in the world 
where these drugs can still be relied 
upon to prevent P. falciparum malaria. 
There are insufﬁ  cient safety data on 
the newer antimalarials to warrant their 
systematic use in pregnant women. IPT 
with sulphadoxine-pyrimethamine (SP) 
has been introduced as an alternative. 
Antimalarial chemoprophylaxis in 
young children has been shown 
to reduce the adverse impact of P. 
falciparum malaria [15,16,17], but this 
intervention never obtained the same 
endorsement as chemoprophylaxis in 
pregnancy. 
Five randomised trials of IPT in 
pregnancy in East Africa have been 
reported [1,2,3,4,5], all with SP, all 
in high-transmission settings, and all 
done between 1992 and 1999 (Table 
S1). The alarming recent increase in 
resistance to SP in Africa confounds 
the cost-effectiveness assessments 
upon which subsequent policy 
recommendations for IPT in pregnancy 
were based [18,19].  
There is no consensus on how IPT 
works, making planning difﬁ  cult. 
This article argues that IPT provides 
mainly intermittent suppressive 
chemoprophylaxis (as opposed to 
treatment effect alone or some other 
magical effects which have never been 
speciﬁ  ed). If this is correct dosing 
schedules should be individualised 
for each antimalarial depending 
on the drug’s pharmacokinetic and 
pharmacodynamic properties. As 
increasing resistance to SP must 
seriously compromise IPT regimens 
based on this drug, the evaluation of 
available new effective antimalarials is 
needed urgently, in both high- and low-
transmission areas. 
Pharmacokinetics
After a treatment dose of SP (25 mg 
sulfadoxine/1.25 mg pyrimethamine 
per kilogram body weight), plasma 
concentrations of pyrimethamine (half-
life, 3 days) and sulfadoxine (half-life, 
7 days) decline log-linearly [20,21]. 
The antimalarial effect depends on 
synergy between the two components, 
but the effect from one treatment 
dose can last as long as 60 days with 
fully sensitive P. falciparum [20,21]. 
For slowly eliminated antimalarial 
drugs (Table S2), the terminal 
elimination phase crosses the in vivo 
dose–response curve (Figure 1). 
Thus, if a full treatment dose is given, 
concentrations at the beginning of the 
terminal elimination phase exceed the 
minimum parasiticidal concentrations 
(MPCs)—the lowest concentrations 
that give maximum effect [22]. The 
exceptions to this are chloroquine 
(and probably piperaquine), as 
resistance to these drugs increases, 
because the elimination of 
chloroquine is multiexponential, 
and the terminal elimination phase 
begins at concentrations that are 
low by comparison with the peak 
concentrations after treatment (Figure 
2). 
The pharmacokinetic properties of 
many drugs are altered in pregnancy; 
lower concentrations often result 
from an expanded volume of 
distribution. Strangely, despite the wide 
endorsement of SP IPT in pregnancy, 
there are no pharmacokinetic studies 
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of sulphadoxine or pyrimethamine in 
pregnancy, so it is not known whether 
the current dosing is optimal. The 
absorption and disposition of many 
drugs are also altered in infancy, 
but there are very few data on 
antimalarial pharmacokinetics 
in the ﬁ  rst year of life. For some 
drugs (e.g., amodiaquine) there 
is insufﬁ  cient information for 
any age group. 
Pharmacodynamics
Is the beneﬁ  t of IPT gained only 
through clearing parasites from 
the placenta (“treatment effect”), 
or is the prevention of new 
infections (“prophylactic effect”) 
an important component? If only 
the treatment effect is important, 
then how long does the 
beneﬁ  cial effect of eradicating 
an asymptomatic low-density 
infection persist for? If it lasts 
until the next infection becomes 
patent (i.e., detectable), then 
rapidly eliminated drugs will 
provide protection only for a 
few days longer than the average 
incubation period (about 
two weeks). Establishment 
of a new placental infection 
(i.e., pathologically signiﬁ  cant 
placental sequestration) may take 
longer because the placenta selects 
and accumulates parasites that bind 
to the proteoglycans chondroitin 
sulphate and hyaluronic acid [23]. If 
only the treatment effect is important, 
then for sustained beneﬁ  t we must 
hypothesise that the parasites that 
persist asymptomatically before IPT is 
given are a selected subpopulation that 
is more pathological than the parasites 
that cause subsequent reinfection. 
This seems implausible in infancy, and 
even in pregnancy it seems unlikely 
that it would take more than ten 
weeks in high-transmission settings 
to re-establish a signiﬁ  cant placental 
infection. This suggests that the 
prophylactic effect is important for the 
efﬁ  cacy of IPT.
The duration of prophylactic effect is 
compromised particularly by resistance. 
For most antimalarials the duration of 
antimalarial effect is a simple function 
of the in vivo concentration–effect 
(dose–response) relationship and 
the pharmacokinetic properties of 
the antimalarial drug [22]. But for 
SP this function is more complicated, 
as synergy between the two 
components needs to be considered. 
The duration of synergy depends 
on resistance levels determined by 
mutations in the parasites’ genes 
encoding dihydropteroate synthase  
and dihydrofolate reductase, the 
respective targets of sulphadoxine and 
pyrimethamine [20,21]. Information 
on this temporal pattern of reinfection 
following IPT in pregnancy or infancy 
is lacking. Such information is essential 
if the choice of drug and the dosing is 
to be rationalised.
Resistance is deﬁ  ned by a right shift 
in the concentration–effect relationship 
and results in reduced effects for any 
concentration below the MPC for 
resistant parasites [24] (see Figure 
1). As the concentration of a slowly 
eliminated antimalarial in the blood 
declines, it continues to suppress the 
growth of newly acquired infections as 
they emerge from the liver. Eventually, 
however, concentrations fall below the 
minimum inhibitory concentration 
(MIC) for the prevalent parasites (i.e., 
the concentration at which the net 
multiplication rate is one), and parasite 
expansion is possible (Figure 3). It 
follows, then, that the duration of “post 
treatment prophylaxis” (PTP) (i.e., the 
length of time after an antimalarial 
treatment dose for which newly 
acquired infections are suppressed) is 
determined by the concentrations of 
the drugs used (determined by dose 
and pharmacokinetics) and 
the sensitivity of the prevalent 
parasites. The more resistant 
the parasites are, the shorter is 
the duration of PTP; for each 
doubling of MIC the duration 
of PTP is shortened by one half-
life (Protocol S1). The triple 
dihydrofolate reductase mutants 
now prevalent across much of 
Africa have an approximate 
1,000-fold reduction in 
pyrimethamine susceptibility, 
which would translate into 
a reduction in PTP of one 
month (Figure 4). As a further 
confounder, folic acid, which is 
prescribed widely in pregnancy, 




In a high-transmission setting 
infections are acquired every 
few days or weeks throughout 
life (see Figure 3). Mortality 
is high in childhood, but by 
the time of adulthood and 
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Summary Points
• Intermittent presumptive treatment 
(IPT) with sulphadoxine-pyrimethamine 
(SP) in pregnancy and with amodiaquine 
or SP in infancy has been proposed for 
use in areas with high levels of malaria 
transmission. 
• The duration of post treatment 
prophylaxis is likely to be an important 
determinant of the beneﬁ  t of IPT.
• Because of rapidly increasing resistance, 
it is very unlikely that IPT in pregnancy 
with SP is as effective now in east Africa 
as it was 5–10 years ago, when it was 
evaluated.
• More effective antimalarial drugs 
such as artemether-lumefantrine 
and particularly dihydroartemisinin-
piperaquine should be evaluated for 
IPT in both low- and high-transmission 
settings.
• Choice of drug, dosing, and dose spacing 
for IPT should be based on a better 
understanding of pharmacokinetics and 
pharmacodynamics.
DOI: 10.1371/journal.pmed.0020003.g001
Figure 1. In Vivo Antimalarial Pharmacodynamics
The parasite burden in an adult (vertical axis) is 
shown in green. After parasite burden expands to the 
point where it causes illness, treatment is given (red 
arrow), which causes a  log-linear decline in parasite 
numbers until concentrations of the antimalarial drug 
(grey shading) fall below the MPC. As the antimalarial 
blood levels fall further, the decline in parasite burden 
slows until it reaches a multiplication rate of one 
(the antimalarial concentration at this point is the in 
vivo MIC). The parasite population then expands to 
cause a recrudescence six weeks later. The sigmoid 
concentration–effect relationship is shown in brown; it is 
depicted in the reverse direction to that normally drawn. 
PMR, parasite multiplication rate. PLoS Medicine  |  www.plosmedicine.org 0030
pregnancy, infections are 
largely asymptomatic—although 
they are often still patent 
(which requires a total burden 
of greater than 100 million 
parasites) [22]. Thus, immunity 
prevents life-threatening parasite 
burdens, and suppresses the pro-
inﬂ  ammatory response (which 
causes illness), but it does not 
prevent infection. 
In pregnancy this immune 
control is impaired in the 
placenta, which acts as a 
“privileged site” for parasite 
multiplication. The objective of 
IPT in pregnancy is to reduce 
or eliminate the adverse effects 
of malaria on maternal anaemia 
and birth weight, and, in 
addition, in a low-transmission 
setting, to prevent severe malaria 
in the mother [25,26]. How 
malaria produces intrauterine 
growth retardation is still 
unresolved, but in P. falciparum malaria, 
retardation tends to be greatest in 
the ﬁ  rst pregnancy, and often occurs 
without maternal illness. The greater 
the placental parasite burden, the 
greater is the reduction in birth weight. 
“Placental malaria”—histological 
evidence of placental accumulation 
of parasitized erythrocytes or malaria 
pigment deposition—has often been 
used as an endpoint in intervention 
studies, although the quantitative 
relationship between placental malaria 
and reduction in birth weight remains 
poorly characterised. 
Preventing Malaria in Infancy
There are fewer data on the efﬁ  cacy 
of IPT in infancy than in pregnancy 
(Table S3). The pharmacodynamics 
of IPT in infancy are probably similar 
to those in pregnancy, although there 
is no “privileged site” for parasite 
multiplication. Protection in the 
ﬁ  rst months of life is mediated by 
a variety of factors, which include 
transplacentally acquired maternal 
antibody (IgG) and a relatively high 
haemoglobin F content in the infants’ 
erythrocytes. After about six months 
of age, protection from these factors 
wanes, and the infant becomes much 
more vulnerable to malaria than the 
mother (because protective immunity 
has yet to be acquired). As delivery of 
antimalarials in the rural tropics is so 
difﬁ  cult, for operational reasons IPT is 
currently being given to infants at the 
same time as the EPI immunisations 
(at 2, 3, and 9 months). This regimen 
leaves a six-month gap between the 
second and third administrations, 
which, even for fully SP-sensitive 
parasites, leaves four unprotected 
months. This is at a time when the 
infant is increasingly vulnerable to 
severe malaria. More information is 
needed on the duration of protection 
afforded by currently available 
antimalarial drugs when administered 
to healthy infants.
Should IPT be Used in Low-
Transmission Settings?
If IPT is just a simple, albeit 
imperfect, way of administering 
chemoprophylaxis, then there are 
also strong arguments for evaluating 
this approach in low-transmission 
settings. The adverse impact of 
malaria in pregnancy is greater in low-
transmission than in high-transmission 
settings. The reduction in the birth 
weight of ﬁ  rst-borne infants is similar, 
but extends to the second and 
subsequent pregnancies; treatment 
failure rates are higher than in non-
pregnant adults [27,28,29]; and there 
is a signiﬁ  cant risk of severe malaria 
with attendant very high mortality. In 
Asia and South America, where low-
transmission areas predominate, P. 
vivax is also an important cause of low 
birth weight, and so useful preventative 
measures must also be effective 
against this infection [30]. 
Antimalarial prophylaxis has 
been recommended and used 
in low-transmission settings, but 
whereas chloroquine remains 
generally effective against P. 
vivax, there are no safe and 
effective available drugs for P. 
falciparum infections. Use of IPT 
in these areas would provide 
a sterner test than in a high-
transmission area because there 
would be little or no background 
immunity to assist antimalarial 
drug efﬁ  cacy. 
What Is the Correct Dose and 
the Correct Interval Between 
Doses?
The dose used in IPT is usually 
the full age- or weight-adjusted 
treatment dose derived either 
empirically or from dose-
ﬁ  nding studies (usually in 
non-pregnant adults). The dose and 
dosing interval should be determined 
by the tolerability, absorption, 
distribution, and elimination kinetics 
of the drug used, and the in vivo 
MIC. Unfortunately, for the two 
drugs that have been used for IPT 
(SP and amodiaquine) there are no 
pharmacokinetic data in pregnant 
women or infants. The in vivo MIC 
is an important measure but it is 
parasite speciﬁ  c and difﬁ  cult to assess 
[31,32,33,34,35]. Ideally, the interval 
between doses should not be more 
than one week longer than the time 
needed for plasma concentrations 
to fall from peak post-dose levels 
to the MIC value. This timing is a 
conservative choice as it assumes all 
infections are equally harmful, and 
it does not take into account either 
the delay in selecting a placenta-
binding P. falciparum subpopulation 
in pregnancy or the delay in achieving 
full growth rates because of continued 
sub-MIC suppression. Although the 
MIC for drugs that are succumbing to 
resistance obviously varies considerably, 
for newer drugs such as lumefantrine 
or piperaquine the variance is 
considerably less and generalisations 
can be made. 
Should an Artemisinin 
Combination Be Used for IPT?
If IPT is simply prophylaxis, then 
a rapidly eliminated artemisinin 
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Figure 2. Blood Concentration Proﬁ  les of Two Antimalarials with 
Different Elimination Proﬁ  les
The examples shown here are meﬂ  oquine (orange) and 
chloroquine (pink). An increase in MIC has different 
effects on the shortening of post-treatment suppressive 
prophylaxis (hatched bars). MICR, MIC for resistant 
parasites; MICS, MIC for sensitive parasites.PLoS Medicine  |  www.plosmedicine.org 0031
component provides very little direct 
beneﬁ  t for the additional cost and 
risk (although the risks are thought 
to be very small in the second 
and third trimesters of pregnancy 
and in infancy). The addition of 
an artemisinin component would 
accelerate parasite clearance and 
prevent gametocyte production, but 
the beneﬁ  ts of this in an asymptomatic 
pregnant woman or child are 
uncertain. The main beneﬁ  t would 
be in providing protection against the 
emergence of de novo resistance to 
the slowly eliminated drug, although, 
because parasitaemias tend to be low, 
the probabilities of de novo selection 
are much lower than 
in acute symptomatic 
infection. But there is a 
genuine concern that if 
monotherapies are made 
available, then they will 
be used and abused, and 
resistance may develop. 
Discussion: The Policy 
Implications
Without a better 
understanding of the 
pharmacodynamic 
effects of IPT, it will be 
difﬁ  cult to make rational 
improvements in this 
promising approach 
to malaria prevention. 
The most parsimonious 
explanation for its 
effectiveness is that IPT 
provides antimalarial 
prophylaxis that, if 
sufﬁ  ciently lengthy and 
effective, is beneﬁ  cial 
both to the pregnant 
woman and the infant. 
But how lengthy and how 
effective? 
For IPT in pregnancy 
the only drug that has 
been evaluated is SP, at 
a time when the drug 
was more effective than 
it is today. A signiﬁ  cant 
improvement in birth 
weight was found 
in only two of four 
randomised trials. In 
a large prospective 
observational study 
conducted in western 
Kenya, IPT was associated 
with an odds ratio of 
0.65 (95% conﬁ  dence interval, 0.45 
to 0.95) for low birth weight [7]. A 
dose–response relationship was found, 
with an adjusted mean increase in birth 
weight of 61 g for each increment in 
the number of SP doses (up to three 
doses). So, two doses of SP did not 
provide maximal beneﬁ  t. But given 
the alarming decline in SP efﬁ  cacy in 
Africa (resulting from rapid spread of 
“quintuple” dihydrofolate reductase/
dihydropteroate synthase mutants that 
are about 1,000 times less sensitive 
to pyrimethamine than wild-type 
parasites), there are grave doubts about 
whether the efﬁ  cacy observed in these 
various studies would still be observed 
today, even if the dosing was increased. 
SP cure rates in children in Malawi—
where IPT in pregnancy is widely 
used—have been consistently less than 
40% for the past ﬁ  ve years [36]. It has 
been suggested that asymptomatic 
pregnant women in high-transmission 
settings may have sufﬁ  cient immunity 
to complement a failing drug—i.e., 
treatment responses would be better 
than in symptomatic children. 
However, if the duration of PTP is the 
main determinant of beneﬁ  t, then this 
beneﬁ  t is shortened progressively by 
increasing resistance (see Figure 4). 
Alternatives to SP are needed urgently.
Is IPT safe? There is no evidence 
to date that IPT is harmful. But the 
incidence of serious adverse effects 
when amodiaquine (agranulocytosis, 
1:2,000) and SP (Stevens-Johnson 
syndrome,1:7,000) were used as 
antimalarial prophylaxis by Western 
travellers was so high that they are 
contraindicated [37]. Both drugs were 
associated with severe hepatitis. Single 
treatments are considered safer, but 
how much safer is not known. There 
are insufﬁ  cient data on the safety 
of amodiaquine in pregnancy [38]. 
The closer IPT comes to continuous 
prophylaxis, presumably the higher 
the risks of serious adverse effects. 
The risk–beneﬁ  t assessment is difﬁ  cult 
to make, but with the current high 
levels of SP resistance, these important 
uncertainties also argue strongly for the 
evaluation of alternatives. Proguanil 
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Figure 3. Hypothetical Parasite Burden Proﬁ  les during 
Pregnancy with SP IPT in a High-Transmission Setting
Entomological inoculation rate is about 50 infectious 
bites per person per year. Note that many infections 
self-cure (each infection is depicted as a green line). 
The hatched bars represent the duration of “suppressive 
prophylactic activity”, and the solid bars represent the 
period during which parasite multiplication is suppressed 
(i.e., levels exceed the in vivo MIC). The horizontal 
dotted line at 108 parasites represents the level at which 
malaria can be detected on a blood ﬁ  lm. (A) represents a 
drug-sensitive area; (B) represents a moderately resistant 
area.
DOI: 10.1371/journal.pmed.0020003.g004
Figure 4. Relationship between MIC and PTP
The proportional increase in malaria 
parasite MIC with resistance is plotted 
against the shortening of the duration 
of PTP, expressed as multiples of the 
terminal half-life. This applies only to 
drugs for which suppressive antimalarial 
prophylaxis occurs in the terminal 
elimination phase (i.e., most drugs).PLoS Medicine  |  www.plosmedicine.org 0032
and quinine are regarded as safe, 
but both are eliminated very rapidly. 
Treatment doses of meﬂ  oquine are not 
well tolerated by healthy subjects, and 
there are safety concerns in pregnancy 
[39]. 
Serious contenders all require 
more than a single dose and will need 
urgent evaluation. These include 
artemether-lumefantrine, although 
more information is needed on 
safety and on the pharmacokinetics 
in pregnancy, and the duration of 
PTP provided by lumefantrine needs 
further assessment. It may be too short. 
Dihydroartemisinin-piperaquine may 
be the most promising candidate. It is 
very well tolerated, and piperaquine 
is slowly eliminated. Indirect evidence 
from the pattern of new infections 
following clinical trials suggests 
protracted suppressive activity. It has 
not yet been evaluated in pregnancy, so 
more information is needed on safety 
and pharmacokinetics in this context. 
For IPT in infancy, however, there 
seems every reason to evaluate this 
drug as soon as possible.  
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